Sirtex accepts $1.4B buyout bid from Chinese consortium, expects to gain regulatory approval

handshake / shaking hands
Australian biotech Sirtex Medical accepted a $1.4 billion buyout offer from China’s CDH Investments and China Grand Pharmaceutical and Healthcare. (daizuoxin/iStock/Getty Images Plus/Getty Images)

Sirtex Medical, which makes a liver cancer treatment, accepted a $1.4 billion buyout offer from China’s CDH Investments and China Grand Pharmaceutical and Healthcare in a deal it expects to win regulatory approval.

The Chinese consortium outbid a previous offer by U.S.-based Varian Medical Systems by pledging to buy 100% of Sirtex stock at $25.10 per share. Sirtiex said that it expects to win approval from Australia’s Foreign Investment Review Board despite recent tensions between the two countries, Reuters reported

Sirtex, an Australian biotech, specializes in the treatment of liver cancer with its lead product SIR-Spheres, which are radioactive beads that target high doses of radiation to liver tumors. Sirtex has manufacturing capabilities in the U.S., Singapore and Germany.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Based on the materially higher offer price and our evaluation of the associated risks, the board of Sirtex has formed the unanimous view that the CDH-CGP proposal is a superior proposal and is in the best interest of shareholders,” Dr. John Eady, Sirtex interim chairman, said in a statement.

Earlier this year, U.S.-based Varian Medical Systems made a surprise $1.3 billion bid for Sirtex that the board of directors initially supported. As a result of the CDH deal, Sirtex will have to cough up about $12 million for a break-up fee with Varian.

If shareholder and regulatory approvals are reached, Sirtex expects the deal to close in September.

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

A new digital health startup is exiting stealth mode with its advanced, long-lasting patient monitoring device—and touting a quick FDA clearance.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.